Rigel Pharmaceuticals Balance Sheet
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals financial position
At the end of fiscal 2025, Rigel Pharmaceuticals reported total assets of $513.6 million, up 213.2% from a year earlier against total liabilities of $122.1 million. Shareholders' equity stood at $391.5 million, or 76.2% of assets. The company held $40.6 million in cash and equivalents against $52.5 million of debt, a net debt position of $11.9 million.
The current ratio (current assets divided by current liabilities) was 2.42, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.13.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 40.58M | 56.75M | 32.79M | 24.46M | 18.89M | 30.37M | 22.52M | 76.32M | 38.29M | 17.63M |
| Short-Term Investments | 114.38M | 20.57M | 24.15M | 33.75M | 106.08M | 26.95M | 75.56M | 52.22M | 77.46M | 57.13M |
| Receivables | 51.76M | 41.62M | 30.55M | 40.32M | 15.47M | 15.97M | 10.11M | 4.08M | 0 | 0 |
| Inventory | 11.51M | 6.00M | 5.52M | 9.12M | 6.62M | 1.64M | 1.35M | 894.00K | — | — |
| Total Current Assets | 240.17M | 135.10M | 99.27M | 115.90M | 154.47M | 88.98M | 119.00M | 136.99M | 117.43M | 76.21M |
| Property, Plant & Equipment | 30.00K | 92.00K | 165.00K | 857.00K | 2.18M | 2.68M | 2.16M | 1.39M | 875.00K | 1.16M |
| Intangible Assets | 24.75M | 27.10M | 13.88M | 14.95M | — | — | — | — | — | — |
| Total Assets | 513.59M | 163.98M | 117.22M | 134.28M | 167.33M | 110.38M | 147.57M | 139.11M | 119.11M | 78.13M |
| Accounts Payable | 7.19M | 3.34M | 7.14M | 22.51M | 3.79M | 3.71M | 4.15M | 6.39M | 2.64M | 5.56M |
| Total Current Liabilities | 99.24M | 63.30M | 53.27M | 65.21M | 63.55M | 40.84M | 58.21M | 27.73M | 18.34M | 22.59M |
| Long-Term Debt | 52.50M | 60.00M | 60.00M | 40.00M | 20.00M | 20.00M | 10.00M | — | — | — |
| Total Liabilities | 122.11M | 160.69M | 145.87M | 147.90M | 136.95M | 76.35M | 93.75M | 29.23M | 18.46M | 23.11M |
| Shareholders' Equity | 391.48M | 3.29M | -28.64M | -13.62M | 30.37M | 34.03M | 53.81M | 109.88M | 100.65M | 55.03M |
| Retained Earnings | -1.02B | -1.39B | -1.41B | -1.38B | -1.32B | -1.31B | -1.28B | -1.21B | -1.14B | -1.06B |
| Total Debt | 52.50M | 60.00M | 60.00M | 40.00M | 20.00M | 20.00M | 10.00M | — | — | — |
| Net Cash (Debt) | 102.45M | 17.32M | -3.07M | 18.21M | 104.97M | 37.33M | 88.08M | 128.54M | 115.75M | 74.77M |
| Shares Outstanding | 18.31M | 17.71M | 17.48M | 173.40M | 171.60M | 169.32M | 167.99M | 167.17M | 146.81M | 99.27M |
This table shows 10 annual periods of Rigel Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RIGL's reporting calendar. What is a balance sheet?